Details
May 18, 2021
12:00PM - 1:00PM
2020 Landmark Trials in Hematology/Oncology: Pharmacist Journal Club
WEBINAR
Intended Audience
This continuing education program was designed specifically for pharmacists and pharmacy technicians.
Pharmacist Learning Objectives:
At the completion of this activity, pharmacists will be able to:
1. Describe the mechanism of action and toxicities of lurbinectedin.
2. Evaluate the evidence supporting pembrolizumab for treatment of MSI-H colorectal cancer.
3. Discuss the strengths and limitations of oral azacitidine for maintenance AML treatment.
4. Design a monitoring and management plan for belantamab-induced ocular toxicities.
To view the full agenda, click here.
Continuing Education Credits:
1.0 contact hour; Knowledge-based; Release Date: 05/18/21; Expiration Date: 05/15/22
Michigan Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Click Here to Register Today!
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
